Subscribe
Subscribe

Industrial application

Rejuvenate Biomed appoints life sciences leader Dr. Ajit Shetty as Chair of the Board of Directors to help guide international ambitions

Augustine Therapeutics appoints Gerhard Koenig as Chairman of the Board, forms Clinical Advisory Board, and broadens therapeutic indications

Leuven, Belgium, 10 May 2022 – Augustine Therapeutics, a biotech company developing novel therapies for neuromuscular and neurodegenerative disorders, appoints Gerhard Koenig as Chairman of the Board. The company also expands the Scientific Advisory Board with clinical experts to support broader therapeutic applications, exploring the potential of novel HDAC6 inhibitors in Charcot-Marie-Tooth disease (CMT), and now also in other indications such as chemotherapy-induced peripheral neuropathy (CIPN), and amyotrophic lateral sclerosis (ALS).

miDiagnostics launches its CE-IVD certified ultra-fast COVID-19 PCR test

IBA and SCK CEN partnership to produce rare radioisotope for cancer treatments

The radioisotope Actinium-225 shows clear promise in the battle against cancer, but to fulfil its potential we will need to enable large-scale production of the rare substance. A collaboration between IBA – the world’s leading company in particle accelerator technology – and the Belgian Nuclear Research Center (SCK CEN) now makes this crucial step possible. The partners are constructing a production plant on the SCK CEN site in the Flemish city of Mol.

Drug development trends: from common to orphan indications… and back again?

Over the past few decades, pharma has gradually shifted its target patient focus for newly launched drugs from large to niche populations. What has caused this trend, and is the pendulum of drug development swinging back again?

VIB: a new focus on data science with Christine Durinx at the helm

Christine Durinx has been appointed as the new co-Managing Director of the world-class life sciences research institute VIB. Taking over from Jo Bury, Durinx joins VIB’s other co-Managing Director Jérôme Van Biervliet in ushering in a new era of discoveries increasingly driven by data science.

Christine Durinx joins VIB as co-managing director

Belgium, 20 April 2022 – VIB and Flemish Minister of Economy and Innovation Hilde Crevits announce the appointment of Dr Christine Durinx as VIB’s co-managing director, alongside Dr Jérôme Van Biervliet. Dr Jo Bury, co-founder and co-managing director since VIB’s inception 25 years ago, is passing the torch to Durinx who is the former Executive Director of the SIB Swiss Institute of Bioinformatics. Her appointment strengthens VIB’s commitment to focus on the burgeoning fields of data science and personalized health.

Solvay Brussels School of Economics and Management joins forces with the Belgian life sciences ecosystem to train the next generation of Biotech and MedTech leaders

miDiagnostics welcomes Nicolas De Clercq as its new Chief Financial Officer

Rejuvenate Biomed Started a Groundbreaking Clinical Trial and Expands for Future Growth

New incubator biotope by VIB launches to support biotech startup teams on their journey to success

Antimicrobial Resistance – the hidden killer we’re ignoring

Antimicrobial Resistance has become an enormous challenge for global health, yet remains largely ignored by companies. As this deadly race worsens, we urgently need to address the huge mismatch between the need and incentive for developing new antimicrobial drugs.

Abscint labels antibodies with radioactive material to spot harmful cells

Abscint is one of several Belgian biotech companies using single-domain antibodies. But unlike the others, Abscint is using these antibodies for diagnostic purposes instead of therapeutic ones. After being labelled with a miniscule amount of radioactive material, the antibodies can be used to show on PET/CT scans for example whether breast cancer cells have spread to the brain, or if patients with sarcoidosis are at risk of a sudden cardiac arrest. The company, founded in 2020, is currently looking for funding to bring its solutions to the market as soon as possible.

Eye implant from iSTAR Medical keeps glaucoma under control

Glaucoma is the leading cause of irreversible blindness, affecting around 100 million people worldwide. Good news though: the innovative implant MINIject – developed by Wavre-based company iSTAR Medical –  has the capacity to prevent progression of the eye disease. The first commercial MINIject implantations are currently being done in Germany, with other European countries to follow soon and a trial in the US underway.

V-Bio Ventures’ Portfolio Company Precirix raises EUR 80 million in Series B to advance its pipeline of precision radiopharmaceuticals